Bitter Melon Peptide (mcIRBP-19 / MAP30) for Obesity

Verdict: Bitter melon peptide does not aid weight loss

Bitter melon peptide is not an evidence-based treatment for obesity: there are essentially no peptide-specific human weight-loss trials, and the broader bitter melon evidence consistently shows no meaningful effect on body weight or body fat.

D 🔴 D Counter-Evidence Insufficient Evidence

🔬Why this grade7-layer evidence engine

This earns a Counter-Evidence (D) grade chiefly because the marketed ingredient is a bitter melon peptide (mcIRBP-19/BmpP), yet no human trial has tested that peptide for obesity. The only peptide-specific RCT (PMID 32354072, n=42, industry-funded) measured blood sugar in people with diabetes, not body weight, so peptide-for-weight-loss evidence is effectively zero.

Stepping back to whole bitter melon, three meta-analyses converge on the same null result. Two 2024 analyses found no significant change in body weight, BMI, waist circumference, or body fat (PMID 39079610, n=448; PMID 38274207, n=414), with the latter concluding the metabolic effect 'cannot be determined' given short trials and very high heterogeneity. A small 2022 pilot in patients with obesity also showed no anthropometric change (PMID 35507955).

Authorities reinforce this. The US FDA warned that a bitter melon blood-sugar supplement is 'not generally recognized as safe and effective,' the NIH notes only a modest glucose effect with little impact on key markers, and the WHO, Mayo Clinic, Harvard, and obesity-medicine societies do not list it for weight management. Most trials also carry industry funding, further weakening confidence.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.41
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
D · Insufficient Evidence
Confidence
82%
Highly consistent evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L11 AI re-checkIndependent read
0.20
L2 PubMedPrimary literature
0.40
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
L5 Clinical bodiesAuthoritative stance
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.406
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 negative 主導 (3 negative > 0 positive),下層 RCT 不能推翻
  4. apply_hec_override — HEC-1 高階證據 negative — 強制由 C 改為 D
  5. tier_strict_requirement_check — Tier 條件達標,未降階
  6. detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
  7. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

The effects of bitter melon (Momordica charantia) on anthropometric indices in adults: A SR/MA of RCTs
PMID: 39079610 2024 統合分析 n = 448
Finding: No significant effect on BW (WMD 0.04 kg, 95% CI -0.16 to 0.25, p=0.651), BMI (WMD -0.18 kg/m^2, 95% CI -0.43 to 0.07, p=0.171), WC (WMD -0.95 cm, 95% CI -3.05 to 1.16, p=0.372), or %BF (WMD -0.99, 95% CI -2.33 to 0.35, p=0.141).
🟢 High quality Academic Effect size: [object Object]
View on PubMed
The metabolic effect of Momordica charantia cannot be determined based on the available clinical evidence: SR/MA of RCTs
PMID: 38274207 2024 統合分析 n = 414
Finding: No significant effect on body weight (MD -1.00 kg, 95% CI -2.59 to 0.59, I^2=97%), BMI (MD -0.42, 95% CI -0.99 to 0.14, I^2=95%), WC (MD 0.72 cm, 95% CI -3.36 to 4.80) or body fat (MD -1.21, 95% CI -2.62 to 0.20). Authors conclude metabolic effect 'cannot be determined' due to short trials, high heterogeneity, low evidence quality.
🟢 High quality Academic Effect size: [object Object]
View on PubMed
Bitter Melon on Weight Loss and Body Composition: SR & Dose-Response MA of RCTs (Amini et al., J Food Biochem)
PMID: 2025 統合分析
— See PubMed for details
View on PubMed
Effect of Momordica charantia on Anthropometric Measures and Metabolic Profile in Patients with Obesity: Pilot RCT
PMID: 35507955 2022 RCT (double-blind) n = 24
Finding: No significant within- or between-group reductions in body weight, BMI, WC, or %BF in the MC arm at 12 weeks. Triglycerides and VLDL decreased significantly (p<=0.05). Placebo group gained weight/BMI. Small pilot.
🟠 Limited quality
View on PubMed
mcIRBP-19 of Bitter Melon Peptide Effectively Regulates DM Patients' Blood Sugar Levels
PMID: 32354072 2020 RCT (double-blind) n = 42
Finding: Improved fasting glucose/HbA1c in T2DM; trial did NOT report anthropometric/obesity endpoints as primary outcomes. The only peptide-specific human RCT identified — but evaluates diabetes, not obesity/weight.
⚠️ Industry-funded
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
Diabalance Diabetes Supplement ... bitter melon, dandelion, bilberry and ginkgo biloba ... marketed to help balance blood sugar levels for people with diabetes ... not generally recognized as safe and effective ... and therefore constitute new drugs source↗
L4d TW TFDA / 衛福部
Supportive
本產品經動物實驗結果顯示:有助於延緩飯後血糖上升,但人體試驗結果不顯著。本產品屬保健食品,不能取代藥品。 source↗
L5a NIH Office of Dietary Supplements
Cautious
In placebo controlled clinical trials in patients with diabetes or glucose intolerance, bitter melon extracts have had only a modest effect on serum glucose levels and little or no effect on fasting plasma glucose or hemoglobin A1c levels. source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-obesity-INT-bitter-melon-peptide-001 繁體中文版 →